Drug pricing & reimbursement in Saudi Arabia.
How the SFDA sets a medicine's price — a value-based decision benchmarked against a basket of reference countries — why that price only erodes over the lifecycle (the −25% generic and −20% biosimilar cuts, the 30% re-pricing cap, the two-year rule), and how a price turns into reimbursement through NUPCO and the Council of Health Insurance — now underpinned by a mandatory health-economic dossier.
From price file to a published ceiling
The SFDA Pricing Committee sets the price of every medicine before it reaches the market. Steps marked gate are the ones that actually decide the number — the mandatory economic-evaluation dossier and the price decision itself.
The company files a pricing application with a recent Price Certificate (Form 16) carrying the ex-factory price, the wholesale price in the country of origin, and the ex-factory/export prices in every country where the product is marketed. The certificate must be ≤6 months old at the time of pricing.
Financial fees are paid upon approval to submit the application, settled through a SADAD invoice (Saudi Arabia's national bill-payment system). The Rules set out the process; they do not publish the SAR fee amount.
Since 1 July 2025 an Economic Evaluation Study (a health-economic / HTA dossier — e.g. a cost-utility analysis) is mandatory for products undergoing registration, re-evaluation or renewal. The published cost-effectiveness threshold is SAR 50,000–75,000 per QALY (quality-adjusted life year).
The Pricing Committee benchmarks the proposed price against the same product's prices in SFDA's basket of reference countries, alongside the prices of therapeutic alternatives already registered in the Kingdom. SFDA may revise the reference-country list periodically.
The Committee sets the price weighing added therapeutic value, registered alternatives, pharmacoeconomics, and the reference/origin prices. The figure it sets is a MAXIMUM price — the company may sell lower, but not higher.
The approved price is applied and published per SFDA's price-implementation procedure, and the product can be marketed at (or below) that ceiling.
The company or its agent may appeal the price within 60 days of being notified of the new price. (No appeal is allowed for the optional pre-registration pricing service.)
The figure the Committee approves is a maximum (ceiling) price — a company may sell below it but not above it S1, Art. 23. There is no single published formula (lowest vs average reference price); the Rules describe a value-plus-reference judgement, so the exact reference mechanic is to verify against SFDA.
Why the price only goes one way: down
The price you defend at launch is the price you erode from. The Rules hard-wire the erosion: the innovator is cut the moment a follower registers, and each generic is capped lower than the last. The bars below index every ceiling to the launch price (= 100%).
Read the cuts as rules, not estimates: the innovator drops 25% when the first generic registers S1, Art. 4, and generics are capped at 70% / 65% / 60% of the pre-cut innovator price by entry order S1, Art. 5. Being the first generic is worth roughly ten points of ceiling over being the third.
| Biologic track | Price ceiling | The rule | Source |
|---|---|---|---|
| Biologic after 1st biosimilar | −20% | Reference biologic cut by 20% when the first biosimilar registers. | S1, Art. 6 |
| 1st biosimilar | ≤75% | First biosimilar priced at ≤75% of the pre-cut biologic price. | S1, Art. 7A |
Biologics follow a parallel, gentler ladder: the reference biologic is cut 20% on first-biosimilar entry, and the first biosimilar is capped at 75% S1, Art. 6 · 7 — versus the steeper −25% / 70% small-molecule path.
Re-pricing: the levers that move a live price
A Saudi price is never finally settled. The Committee can re-evaluate it through the product's life — but the Rules also bound how fast and how far a price can fall, which is what makes erosion forecastable.
The two guard-rails that matter for planning: any single cut is capped at 30% S1, Art. 9, and no price can be cut again within two years of its last reduction S1, Art. 22 — a hard cool-off that turns re-pricing into a schedulable event rather than a continuous risk.
From an approved price to reimbursement
A price is permission to sell, not a guarantee of revenue. In Saudi Arabia the public side runs through one central buyer (NUPCO) and the private side through one insurance formulary (CHI) — and a health-economic case now sits underneath both. The list below is the practical access chain; the public/private mechanics are advisory-described, so they carry a verify marker.
From price-taker to value: the HTA mandate
The biggest change to KSA pricing in years: as of 1 July 2025, an economic-evaluation (HTA) dossier is mandatory — the system is moving from pure reference pricing toward value-based pricing, in line with Vision 2030.
The mandate and the SAR 50,000–75,000 / QALY threshold are stated in the official SFDA EES guideline (v1.1) S2; the guideline calls the threshold “estimated” with case-by-case flexibility, so treat it as a guide value, not a hard cutoff. The review-window timing is advisory-sourced to verify and the central HTA body is still maturing.
Where is your price decided?
The pricing playbook splits cleanly by product type: an innovator defends a value-set ceiling against erosion; a follower captures a mechanical ceiling and then competes on volume.
- Build the EES / value dossier before pricing — it is mandatory and it anchors the ceiling
- Manage your international price corridor — low reference-market prices pull the Saudi price down
- Model the −25% (generic) / −20% (biologic) step the day the first follower registers
- Entry order sets your ceiling — being first generic (≤70%) beats being third (≤60%)
- The list price is a ceiling; competition and tenders decide the realized price
- NUPCO procurement is where public-sector volume is won or lost
Most of this guide is quoted directly from primary SFDA regulation. These are the few items that are not pinned to a single primary document — the things to confirm with SFDA, NUPCO or CHI before treating them as final.
- The actual LIST of reference (basket) countries is NOT fixed in the Pricing Rules — Art. 2 keeps it in the Price Certificate Form and says SFDA 'may review the list of reference countries periodically'. Public advisory lists DISAGREE (a ~15–16-country list vs an expanded ~21-country list incl. GCC/MENA peers). We therefore do not assert a specific country list here — confirm the current basket directly with SFDA.
- Whether the benchmark uses the lowest, the average, or a weighted reference price is not stated as a single rule in DS-REQ-082; the Rules describe a value-plus-reference judgement by the Committee, not a fixed formula. Do not present a single mechanical reference rule as fact.
- The SAR fee amounts for pricing / pre-pricing / re-pricing are NOT published in the primary Rules (the process and the SADAD step are). Any specific SAR pricing-fee figure seen elsewhere is consultancy-sourced — verify before quoting.
- The cost-effectiveness threshold (SAR 50,000–75,000 / QALY) is stated in the official EES guideline (S2) as an 'estimated' threshold with case-by-case flexibility — treat it as a guide value, not a hard cutoff.
- NUPCO-as-public-reimbursement and the CHI Insurance Drug Formulary mechanics are described by official body pages (S5/S6) and advisories (S9) rather than a single reimbursement statute — confirm current tender, formulary and co-payment specifics with NUPCO / CHI directly.
- The central HTA body, its remit and the ~60–90-day review window are emerging and advisory-sourced (S9/S10); verify the current institutional setup before relying on timings.
The RaqibHealth angle
Pricing and reimbursement sit downstream of the SFDA register — the events that move a Saudi price (a generic entry, a loss-of-exclusivity, a new competitor) surface first as register activity that RaqibHealth tracks.
Where every figure comes from
Official SFDA / government sources are marked in green. The pricing rules, ladders, caps and the two-year rule are quoted from the primary SFDA Pricing Rules (S1); the mandatory economic-evaluation dossier and the QALY threshold are from the official SFDA EES guideline (S2). NUPCO / CHI body pages and reputable advisories corroborate the reimbursement chain.
This guide is informational and not legal, regulatory or tax advice. Saudi pricing and reimbursement rules change — the SFDA reference-country basket, fee amounts, the economic-evaluation requirements and the NUPCO / CHI reimbursement pathways are all subject to revision — so always confirm against the SFDA, NUPCO and CHI primary sources before acting. RaqibHealth cites its sources on every record. info@raqibhealth.com · RaqibHealth home